AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01497886 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Education program
Description: The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence).
Study NCT04103827 — intervention group
Intervention type: OTHER
Intervention: usability assessment
Description: Usability of Le Qoos will be assessed using a validated usability questionnaire
Study NCT02368743 — intervention group
Intervention type: DRUG
Intervention: mesalazine
Study NCT03126565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifeline CareSage Flagging
Description: Patients in the intervention group will receive active monitoring by the CareSage risk assessment platform and clinical interface, including nurse triage calls and tailored PHH interventions. Beginning at month 4, the CareSage algorithm will assess patients' risk for emergency transport every 30 days. Patients identified as high risk will receive nurse triage calls and, depending on their needs, tailored care according to a stepped-care approach. The principal goals will be to reinforce the patients' education, ensure compliance with medications and diet, and identify recurrent symptoms amenable to treatment on an outpatient basis to avoid readmissions
Study NCT01443091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of mother's own colostrum
Description: application of 0.2mL of mother's own colostrum to the infant's oropharyngeal mucosa every 3 hours for 5 days (day of life 2 until day of life 7)
Study NCT01443091 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: application of sterile water
Description: application of 0.2mL sterile water to the infant's oropharyngeal mucosa every 3 hours for 5 days (from day of life 2 until day of life 7)
Study NCT02973334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ingestion of artificially-sweetened beverages
Description: From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing non nutritive sweeteners (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
Study NCT02973334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ingestion of sugar-sweetened beverages
Description: From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing sugar (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
Study NCT02973334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of water
Description: From t=60 to the end of the metabolic test, volunteers will ingest 7 water beverages (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
Study NCT04621526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine- ketamine
Description: patients will receive combination of ketamine 1mg/kg and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
Study NCT04621526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine- propofol
Description: patients will receive combination from 0.5 mg/kg propofol and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
Study NCT02525601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon CR cemented
Description: Implantation of Knee Prosthesis
Study NCT02525601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon CR uncemented
Description: Implantation of Knee Prosthesis
Study NCT02231281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cART(TDF/AZT+3TC+LPV/r)
Description: Standard antiretroviral therapy for HIV infection
Study NCT02231281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTL infusion
Description: cART(TDF/AZT+3TC+LPV/r) plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
Study NCT01200732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil, placebo
Description: 20mg tablets, 2 tablets Once daily(i.e 40mg once daily) 20mg placebo 2 tablets once daily
Study NCT01200732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tadalafil, placebo
Description: 20mg tablets, 2 tablets Once daily(i.e 40mg once daily) 20mg placebo 2 tablets once daily
Study NCT00993759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3804-250A
Description: 3.2 ml applied topically after hand washing and at least every 3 hours while awake.
Study NCT00371644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the rape.
Study NCT00371644 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present-Centered Therapy
Description: PCT consists of general support and education focused on current issues in the patient's life. It emphasizes the focus on the individual's current life, and conceptualizes the problems addressed as manifestations of PTSD that, in some cases, may have been present for long periods of time. Emphasis is on problem solving and improving relationships. Connections are made between current problems and PTSD symptoms. PCT provides the emotional support for the trauma patient that is thought to help in recovery and helps the victim gain a better understanding of the nature of the patient's problems and connection with PTSD.
Study NCT03482076 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: transferrin receptor concentration
Description: Sandwich radio-imunoassay
Study NCT01311518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Placebo
Description: Injectable administration by slow intravenous bolus, 0.00% Thymosin Beta 4 daily for 3 days then weekly for 4 consecutive weeks
Study NCT01311518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Injectable Thymosin beta 4
Description: Injectable administration of Thymosin Beta 4 by intravenous bolus at 1200 mg, or 450 mg daily for 3 days then weekly for 4 consecutive weeks
Study NCT00331513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vorinostat
Description: Given orally
Study NCT00331513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: idarubicin
Description: Given IV
Study NCT00331513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00331513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT02669082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon tablets
Study NCT03932149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Description: The target is left DLPFC and the iTBS protocol is: 70% of RMT; triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
Study NCT03932149 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: The target is right DLPFC and the sham stimulation protocol is: triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
Study NCT02034812 — intervention group
Intervention type: OTHER
Intervention: Decipher Questionnaire
Description: Pathological data from 12 de-identified patient cases will be reviewed by at least 25 Radiation Oncologists before and after exposure to the Decipher test results. Given the number of patient cases, reviewed by each participant, this allows for assessment of decision making based on 300 patient case reviews at each time point, immediately following RP and at the time of PSA rise.
Study NCT02930746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-092)
Study NCT00971035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab (MILR1444A)
Description: Subcutaneous repeating dose
Study NCT00971035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous repeating dose
Study NCT02494375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep and glucose assessments
Description: Sleep characteristics, glycemic control, salivary amylase and body composition will be assessed 3 times, at 3-4 months intervals
Study NCT01366859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months to determine the supplement's effect in core areas of behavior in children with autism.
Study NCT01366859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice Protein (Placebo)
Description: The control or placebo study group will consist of thirty children that will be treated with rice protein (placebo) 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
Study NCT04649918 — intervention group
Intervention type: OTHER
Intervention: pulmonary rehabilitation
Description: COVID 19 patients perform a standardized 3-week inpatient pulmonary rehabilitation program
Study NCT03326284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 g protein hypocaloric
Description: Following a 5 day hypocaloric diet one group of 10 women will ingest 15 g of protein
Study NCT03326284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35 g protein hypocaloric
Description: Following a 5 day hypocaloric diet one group of 10 women will ingest 35 g of protein
Study NCT03326284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60 g protein hypocaloric
Description: Following a 5 day hypocaloric diet one group of 10 women will ingest 60 g of protein
Study NCT03326284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35 g protein energy balance
Description: Following a 5 day energy balanced diet one group of 10 women will ingest 35 g of protein
Study NCT03936335 — intervention group
Intervention type: DRUG
Intervention: dupilumab
Description: No study drug will be administered. This study is based on an analysis of automated medical and prescription claims, supplemented by information abstracted from the medical record.
Study NCT04678427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 Minute Walk Functional Test
Description: Complete 6-minute walk test
Study NCT04678427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in walking and other activities
Study NCT04678427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study NCT04678427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timed Get Up and Go Test
Description: Complete timed get up and go test
Study NCT01794793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.
Study NCT01794793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.
Study NCT01794793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Long Acting Release is administered by a single intramuscular (i.m.) monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
Study NCT03962543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib (PD-0325901) oral capsule or dispersible tablet
Description: Mirdametinib (PD-0325901) capsule or dispersible tablet
Study NCT04291664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone Acetate 1000mg will be administered orally once daily
Study NCT04291664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5Mg Tab
Description: Prednisone 5mg will be administered orally twice daily with Abiraterone Acetate 1000mg~Prednisone 5mg will be administered orally twice daily with DST-2970 for 28 days after dosing of Abiraterone Acetate is stopped
Study NCT04291664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DST-2970 (Abiraterone)
Description: DST-2970 will be administered orally twice daily for 28 days (for every cycle) after dosing of Abiraterone Acetate is stopped
Study NCT04308980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Specialized product for medical nutrition (SPP-1)
Description: Patients randomly allocated to this group will use specialized product for medical nutrition (SPP-1). This product contains: soy protein, whey protein concentrate, microcapsulated rapeseed oil, maltodextrin, inulin, Polydextrose, soy lecithin, potassium citrate, magnesium lactate, ω-3 PUFA (docosahexaenoic acid), sweetener mixture (stevia extract, erythritol), natural flavor Yogurt-vanilla, calcium carbonate, betaine hydrochloride, natural flavor raspberry, vitamin premix (vitamins a, e, C, D3, B1, B2, B6, B12, PP, folic acid, Pantothenic acid, K1, Biotin), beet juice concentrate, carrageenan, mineral premix (iron, zinc, copper, manganese, iodine, selenium, molybdenum, chromium), alpha-lipoic acid. The product is packed in approved by sanitary rules bags by 30 g. The instant drink obtained by the mixture of the bag content with warm (30-60C) water should be used immediately after being prepared. The daily dose is 1 pack TID
Study NCT04308980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized diet
Description: All the patients enrolled to the study will be provided with recommendations on diet. Individualized requirements will be calculated based on the results of indirect calorimetry (resting energy expenditures) and measurements of urea in daily urine
Study NCT04308980 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: individualized diet
Description: All the patients enrolled to the study will be provided with recommendations on diet. Individualized requirements will be calculated based on the results of indirect calorimetry (resting energy expenditures) and measurements of urea in daily urine
Study NCT02036658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Group Therapy
Description: Cognitive Behavioral Group Therapy for social anxiety disorder is a 12-week treatment that involves psychoeducation, cognitive restructuring and exposure to social situations.
Study NCT02036658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction
Description: Mindfulness-Based Stress Reduction will be completed in 12 weeks in the study and includes enhancing one's awareness non-judgmentally by focusing on the present moment through the use of mindfulness meditation.
Study NCT01027728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX 354-C
Description: * Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days;~* Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and~* Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days.
Study NCT02400567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracile
Study NCT02400567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Study NCT02400567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT02400567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT02400567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Study NCT03701698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Oral Tablet
Description: Ruxolitinib Oral Tablet （Jakafi）, 5\~10mg bid po for at least 28 days.
Study NCT03701698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone: 2mg/kg/d , iv or iv gtt, for at least 1 week, then taper accordingly.
Study NCT04836364 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention; observation only.
Study NCT00415597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Description: capsules, available dosage strengths 20, 30, 40, 50, 60, 80, and 100 mg morphine sulfate with 4% by weight naltrexone hydrochloride given once or twice daily
Study NCT03646305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Defusion
Description: Cognitive defusion aims to change one's relationship to their thoughts - as opposed to changing the content, form, or frequency - by reframing internal experiences as less threatening (Hayes, Luoma, Bond, Masuda, \& Lillis, 2006). It is the process of detaching the link between one's thoughts and perceptions of reality and acknowledging the role one's thoughts play in their internal events. A number of techniques have been developed to remove the literal quality of such thoughts, including repeating the thought, and, more recently, singing the thought.
Study NCT04329091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: All subjects will receive Dexmedetomidine to induce sedation between their pre-sedation and post-sedation perceptual learning tests.
Study NCT02193139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WL8713, 6 mg
Study NCT02193139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WL8713, 12 mg
Study NCT02193139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WL8713, 18 mg
Study NCT02193139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WL8713, 24 mg
Study NCT02193139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04198584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VC-CBCS
Description: A 14-module stress management and lifestyle group-based intervention delivered via videoconferencing WebEx technology to participants who have/had chronic hepatitis C and experience symptoms, stress or lifestyle requirements to promote liver health.
Study NCT00722566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE Administered by subcutaneous injection
Description: Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle
Study NCT00722566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VELCADE Administered by intravenous infusion
Description: Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.
Study NCT03870776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP4343
Description: Daily oral administration of MAP4343
Study NCT03870776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral administration of Placebo
Study NCT04045184 — intervention group
Intervention type: OTHER
Intervention: Food assistance
Description: This is an observational study of an existing community program. No intervention is provided beyond food assistance in the community program.
Study NCT01276522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Monthly subcutaneous injection with 150mg Canakinumab for 6 months
Study NCT00381238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: Extended Release Tablets
Study NCT00067769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based intervention UCanPoopToo
Description: Internet-based intervention to administer Enhanced Toilet Training (ETT).
Study NCT00067769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: Routine clinical care.